Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

102 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. Sandborn WJ, et al. Among authors: lyne a. Aliment Pharmacol Ther. 2007 Jul 15;26(2):205-15. doi: 10.1111/j.1365-2036.2007.03361.x. Aliment Pharmacol Ther. 2007. PMID: 17593066 Free article.
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Kamm MA, et al. Among authors: lyne a. Gastroenterology. 2007 Jan;132(1):66-75; quiz 432-3. doi: 10.1053/j.gastro.2006.10.011. Epub 2006 Oct 12. Gastroenterology. 2007. PMID: 17241860 Clinical Trial.
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ. Wilens TE, et al. Among authors: lyne a. J Am Acad Child Adolesc Psychiatry. 2015 Nov;54(11):916-25.e2. doi: 10.1016/j.jaac.2015.08.016. Epub 2015 Sep 15. J Am Acad Child Adolesc Psychiatry. 2015. PMID: 26506582 Clinical Trial.
Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
Connor DF, Findling RL, Kollins SH, Sallee F, López FA, Lyne A, Tremblay G. Connor DF, et al. Among authors: lyne a. CNS Drugs. 2010 Sep;24(9):755-68. doi: 10.2165/11537790-000000000-00000. CNS Drugs. 2010. PMID: 20806988 Clinical Trial.
102 results